Skip To Main Content
Kambiz Rahbar on Muck Rack

Kambiz Rahbar

As seen in: Nature, Wiley Online Library, The Lancet, Journal of Nuclear Medicine, European Urology, UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kambiz

Contact Kambiz, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Update to “Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy”

|
By Ken Herrmann, Kambiz Rahbar, Matthias Eiber
| Journal of Nuclear Medicine Verified
In the article “Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy” (J Nucl Med. 2024;65:71–78), it was identified that calibration factors applied to patients from two contributing sites (Münster and Munich) required correction.
Open in Who Shared Issue with article?

Update to “Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy”

|
By Ken Herrmann, Kambiz Rahbar, Matthias Eiber
| Journal of Nuclear Medicine Verified
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Open in Who Shared Issue with article?

SNMMI 2026: The LuRa Study: Safety and Survival Outcomes of Radium-223 in Patients with mCRPC with Prior 177Lu-PSMA Radioligand Therapy

|
By Zachary Klaassen Verified, Kambiz Rahbar
| UroToday Verified
(UroToday.com) The 2026 SNMMI annual meeting featured a genitourinary radiotherapeutics session and a presentation by Dr. Kambiz Rahbar discussing safety and survival outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC) with prior 177Lu-PSMA radioligand therapy in the LuRa study.
Open in Who Shared Issue with article?
See all 18 articles